Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

16

Revenue 2017

Shire

The Top Pharma List rankings are compiled from GlobalData's pharmaceutical revenue figures, which are based on prescription medicine sales, including generics drugs. They have been compiled below into an infographic of Shire's 2013 CNS, immunology and metabolic's sales performance.

Shire

Pfizer abandons antibody for Duchenne

Pfizer abandons antibody for Duchenne Novartis and Morphosys gave up on their bimagrumab for muscle-wasting disease sporadic inclusion body myositis two years ago, while Shire/Acceleron and Amgen have also chalked up failures in this

Roche highlights Hemlibra data as key FDA date approaches

Roche highlights Hemlibra data as key FDA date approaches every few days, such as Shire’s Adynovate, Biogen’s Eloctate, Bayer’s Kovaltry and CSL Behring’s Afstyla, uptake hasn’t been as quick as hoped. ... centred on a type of blood clot called thrombotic microangiopathy and a legal challenge from

Shire claims US okay for HAE blockbuster-in-waiting

Shire claims US okay for HAE blockbuster-in-waiting Lanadelumab (formerly SHP643) will be sold as Takhzyro in the US and is being tipped as a future blockbuster for Shire. ... Shire is already a player in HAE therapy with three drugs already on the market for the disease that made $1.43bn in sales last

Daily Brief: Orchard raises $150m, Astellas swoops for early-stage gene company, Amicus gets FDA Fabry approval

Daily Brief: Orchard raises $150m, Astellas swoops for early-stage gene company, Amicus gets FDA Fabry approval The most notable example of this is Takeda's $62bn acquisition of specialist pharma company Shire.

Healthcare Comms news

Healthcare Comms news Headed by chief executive Ben Blackmore, the agency has a number of pharmaceutical clients including AbbVie, Allergan, Bayer, Janssen, Merck and Shire.

[ Previous 5 results ] 5 6 7 8 9 10 11 12 13 14 [ Next 5 results ]

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Page & Page

For those who can imagine better, Page & Page is home to meaningful encounters of a marketing, communication and creative kind:...

Latest intelligence

Five companies 20 for 2020
20 for 2020 – Five pharma companies to watch
As a new decade gets into gear, we take a look at five pharma companies that have a lot riding on 2020...
The growing clinical importance of patient-reported outcomes (PROs)
Traditionally, the success or otherwise of medical treatments has been assessed by mortality or clinical assessments of health. However, patient self-reports of health are increasingly seen as central to the...
Generation Z
The roaring ‘20s and Generation Z
How a new generation will shape pharma comms this decade...

Infographics